Aclaris Therapeutics, Inc.
NASDAQ:ACRSBiotechnology
+$0.03 today
- Market cap
- $555.14M
- Beta
- 0.80
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$0.54
Volume 2.94M
Average 1.40M
ACRS Total Liabilities
Everything the company owes to creditors and other parties.
Aclaris Therapeutics, Inc.NASDAQ: ACRS
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities broadly unchanged from a year ago
Total liabilities stood at $55.07M at the end of Q1 FY2026, up 1.9% from a year earlier and down 4.0% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.
Context
- Total liabilities amounted to 27.7% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +1.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 57.38M USD
- Year-over-year change
- -11.4%
- 4-year CAGR
- +1.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 57.38M | -11.4% |
| FY2024 | 2024-12-31 | 64.77M | +61.0% |
| FY2023 | 2023-12-31 | 40.23M | -29.4% |
| FY2022 | 2022-12-31 | 56.98M | +5.8% |
| FY2021 | 2021-12-31 | 53.87M | — |
Total Liabilities vs competitors
How ACRS compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1.9% is the 4th highest of 8, against a peer median of -13.6%.
- Total liabilities amounts to 27.7% of total assets for ACRS, versus a peer median of 20.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $316.94M USD | -18.3% | -2.1% | 96.1% | |
| Mar 2026 | $146.35M USD | +48.3% | +145.8% | 36.6% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $108.46M USD | -13.6% | -28.6% | 19.3% |
| Mar 2026 | $55.07M USD | +1.9% | +0.2% | 27.7% | |
| Mar 2026 | $38.51M USD | +49.2% | +29.7% | 20.3% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $33.11M USD | +108.5% | — | 11.4% |
| Mar 2026 | $24.33M USD | -17.8% | -2.8% | 36.6% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €18.7M EUR | — | — | 11.3% |
| Jun 2026 | $15.58M USD | — | — | 12.1% | |
| Mar 2026 | €12.01M EUR | -27.4% | -0.9% | 24.5% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ACRS) | — | -13.6% | -1.5% | 20.3% | |
Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 27.35M | 45.28M | 39.88M | 24.57M | 19.96M |
| Short-term Investments | 164.07M | 172.29M | 79.23M | 89.02M | 70.79M |
| Net Receivables | 623K | 484K | 298K | 318K | 5.57M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 13.5M | 9.45M | 12.04M | 55.05M |
| Total Current Assets | 205.03M | 231.55M | 128.86M | 125.95M | 151.36M |
| Property, Plant & Equipment (Net) | 1.34M | 1.1M | 1.62M | 1.01M | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 7.05M | 6.97M | 269K | 0 | 0 |
| Long-term Investments | 34.24M | 12.24M | 62.77M | 90.3M | 60.61M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.55M | 2.73M | 3.89M | 3.07M | (51.52M) |
| Total Non-current Assets | 46.18M | 23.05M | 68.55M | 94.38M | 9.1M |
| Total Assets | 251.21M | 254.6M | 197.41M | 220.33M | 160.46M |
| Account Payables | 9.99M | 10.35M | 8.88M | 4.69M | 13.16M |
| Short-term Debt | 0 | 0 | 0 | 0 | 551K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 3.89M | 3.94M |
| Other Current Liabilities | 6.59M | 7.5M | 6.11M | 11.59M | 5.7M |
| Total Current Liabilities | 22.93M | 21.94M | 30.95M | 31.6M | 28.65M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 367K | 367K | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 20.04M | 16.17M |
| Other Non-current Liabilities | 30.57M | 34.67M | 9.27M | 13.14M | 11M |
| Total Non-current Liabilities | 30.94M | 35.04M | 9.27M | 33.18M | 28.73M |
| Total Liabilities | 53.87M | 56.98M | 40.23M | 64.77M | 57.38M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | (595.41M) | (682.32M) | (770.8M) | (902.86M) | (967.78M) |
| Accumulated OCI | (224K) | (897K) | (106K) | 97K | 610K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 197.34M | 197.62M | 157.18M | 155.55M | 103.08M |
| Total Debt | 693K | 684K | 426K | 0 | 2.12M |
| Net Debt | (26.66M) | (44.59M) | (39.45M) | (24.57M) | (17.84M) |
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.